Login / Signup

Developing HDAC4-Selective Protein Degraders To Investigate the Role of HDAC4 in Huntington's Disease Pathology.

Natsuko MacabuagWilliam EsmieuPerla BrecciaRebecca JarvisWesley BlackabyOvadia LazariLiudvikas UrbonasMaria EznarriagaRachel WilliamsAnnelieke StrijboschRhea Van de BospoortKim MatthewsCole ClissoldTammy LadduwahettyHuw D VaterPatrick HeaphyDouglas G StaffordHong-Jun WangJohn E MangetteGeorge McAllisterVahri BeaumontThomas F VogtHilary A WilkinsonElizabeth M DohertyCelia Dominguez
Published in: Journal of medicinal chemistry (2022)
Huntington's disease (HD) is a lethal autosomal dominant neurodegenerative disorder resulting from a CAG repeat expansion in the huntingtin ( HTT ) gene. The product of translation of this gene is a highly aggregation-prone protein containing a polyglutamine tract >35 repeats (mHTT) that has been shown to colocalize with histone deacetylase 4 (HDAC4) in cytoplasmic inclusions in HD mouse models. Genetic reduction of HDAC4 in an HD mouse model resulted in delayed aggregation of mHTT, along with amelioration of neurological phenotypes and extended lifespan. To further investigate the role of HDAC4 in cellular models of HD, we have developed bifunctional degraders of the protein and report the first potent and selective degraders of HDAC4 that show an effect in multiple cell lines, including HD mouse model-derived cortical neurons. These degraders act via the ubiquitin-proteasomal pathway and selectively degrade HDAC4 over other class IIa HDAC isoforms (HDAC5, HDAC7, and HDAC9).
Keyphrases
  • histone deacetylase
  • mouse model
  • genome wide
  • small molecule
  • spinal cord injury
  • spinal cord
  • amino acid
  • binding protein